WILMINGTON, Del., Sept. 19, 2025 /PRNewswire/ -- Brand Engagement Network, Inc. (Nasdaq: BNAI) ("BEN"), an innovator in human-like AI Agents…
MESA, ARIZONA / ACCESS Newswire / September 19, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE), a pioneer in AI-powered…
Pending the European Commission’s final decision, nipocalimab could be the first FcRn blocker approved in both adult and adolescent gMG…
Lunsumio provides high and long-lasting response rates, with approximately two-thirds of patients with a complete response in remission after four…
OVATION 3 pivotal Phase 3 trial is currently advancing IMNN-001, with several patients being treated LAWRENCEVILLE, N.J., Sept. 19, 2025…
neffy 1 mg and 2 mg doses approved by Japanese regulators neffy offers a new delivery method for epinephrine in…
DALLAS, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence…
– Approval triggers $10 million cash milestone payment to Verrica – – YCANTH® approval in Japan addresses significant unmet need…
Bylvay® is the first once-daily ileal bile acid transport inhibitor to be approved as a treatment for pruritus associated with…
Pending the European Commission’s final decision, nipocalimab could be the first FcRn blocker approved in both adult and adolescent gMG…